Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia
Abu‐Sayeef Mirza(University of South Florida), Lohith Gowda(Yale Cancer Center), Reena Jayani(Vanderbilt University Medical Center), Scott F. Huntington(Yale Cancer Center), Michael Byrne(Vanderbilt University Medical Center), Adetola A. Kassim(Vanderbilt University), Francine M. Foss(Yale Cancer Center), Brian G. Engelhardt(Vanderbilt University Medical Center), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Molly Schiffer, Iris Isufi(Yale University), Amer M. Zeidan(Yale Cancer Center), Bipin N. Savani(Vanderbilt University Medical Center), Rory M. Shallis(Smilow Cancer Hospital), Sarah Tinker Perrault, Stuart Seropian(Yale Cancer Center), Nikolai A. Podoltsev
Cited by 0
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2016|538
Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer
|JAMA Oncology|2021|464
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|442